



Published in final edited form as:

Cell Rep. 2018 February 13; 22(7): 1787–1797. doi:10.1016/j.celrep.2018.01.016.

Mechanisms to Evade the Phagocyte Respiratory Burst Arose by Convergent Evolution in Typhoidal *Salmonella* Serovars

Hirota Hiyoshi^{1,4}, Tamding Wangdi^{1,4,*}, Gabriel Lock¹, Cheng Saechao¹, Manuela Raffatellu², Brian A. Cobb³, and Andreas J. Bäuml^{1,5,*}

¹Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, Davis, CA 95616, USA

²Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA

³Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA

SUMMARY

Typhoid fever caused by *Salmonella enterica* serovar (*S.*) Typhi differs in its clinical presentation from gastroenteritis caused by *S.* Typhimurium and other non-typhoidal *Salmonella* serovars. The different clinical presentations are attributed in part to the virulence-associated capsular polysaccharide (Vi antigen) of *S.* Typhi, which prevents phagocytes from triggering a respiratory burst by preventing antibody-mediated complement activation. Paradoxically, the Vi antigen is absent from *S.* Paratyphi A, which causes a disease that is indistinguishable from typhoid fever. Here, we show that evasion of the phagocyte respiratory burst by *S.* Paratyphi A required very long O antigen chains containing the O2 antigen to inhibit antibody binding. We conclude that the ability to avoid the phagocyte respiratory burst is a property distinguishing typhoidal from non-typhoidal *Salmonella* serovars that was acquired by *S.* Typhi and *S.* Paratyphi A independently through convergent evolution.

Graphical abstract

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

*Correspondence: twangdi@wustl.edu (T.W.), ajbaumler@ucdavis.edu (A.J.B.).

⁴These authors contributed equally

⁵Lead Contact

AUTHOR CONTRIBUTIONS


Conceptualization, H.H., T.W., and A.J.B.; Methodology, H.H., T.W., G.L., C.S., M.R., and B.A.C.; Investigation, H.H., T.W., G.L., C.S., M.R., B.A.C., and A.J.B.; Resources, M.R., B.A.C., and A.J.B.; Funding Acquisition, T.W., B.A.C., and A.J.B.; Writing–Original Draft, H.H., T.W., and A.J.B.; Writing–Review and Editing, H.H., T.W., and A.J.B.; Supervision, H.H., T.W., and A.J.B.

DECLARATION OF INTERESTS

The authors declare no competing interests.

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and two tables and can be found with this article online at <https://doi.org/10.1016/j.celrep.2018.01.016>.



INTRODUCTION

Typhoid fever, caused by the human-adapted *Salmonella enterica* serovar (*S.*) Typhi, is a major human disease that is responsible for 21.6 million illnesses annually, whereas paratyphoid fever, associated predominantly with the human-adapted *S. Paratyphi A*, is responsible for 5.4 million cases per year (Crump et al., 2004). Typhoid and paratyphoid fever are indistinguishable in their clinical signs and symptoms (Nuccio et al., 2013), suggesting that typhoidal *Salmonella* serovars possess similar virulence strategies.

The ability to breach an intact mucosal barrier and cause an invasive bloodstream infection in humans is a property that sets typhoidal *Salmonella* serovars apart from non-typhoidal - *Salmonella* serovars associated with gastroenteritis (Kestra-Gounder et al., 2015; Raffatellu et al., 2006; Tsois et al., 2008; Wangdi et al., 2012). Clues regarding the identities of the mucosal barrier functions limiting the dissemination of the non-typhoidal *S. Typhimurium* in individuals with an intact immune system can be gleaned by analyzing the immune defects that put patients at risk of developing bacteremia. Chronic granulomatous disease, which is caused by deficiencies in genes encoding subunits of the phagocyte NADPH oxidase (the enzyme that generates superoxide radicals during the respiratory burst of phagocytes [Hohn and Lehrer, 1975; McPhail et al., 1977; Moellering and Weinberg, 1970; Seger et al., 1983]), renders individuals susceptible to develop non-typhoidal *Salmonella* bacteremia (Winkelstein et al., 2000). Thus, the generation of reactive oxygen species (ROS) by phagocytes is essential for maintaining an intact mucosal barrier impeding *S. Typhimurium* dissemination beyond the mesenteric lymph node in humans. Whereas the phagocyte respiratory burst helps prevent *S. Typhimurium* dissemination in individuals with an intact immune system, *S. Typhi* and *S. Paratyphi A* are able to cross an intact mucosal barrier and spread from the mesenteric lymph node via the circulation to internal organs. A supposition from these observations is that *S. Typhi* and *S. Paratyphi A* must possess virulence

mechanisms for averting the respiratory burst of human phagocytes, but these virulence mechanisms must be absent from *S. Typhimurium*.

A DNA region present in *S. Typhi* but absent from the *S. Typhimurium* genome is the *viaB* locus, which contains genes for the regulation (*tviA*), synthesis (*tviBCDE*), and export (*vexABCDE*) of the Vi antigen (Liston et al., 2016; Virlogeux et al., 1995; Wetter et al., 2012). TviA activates genes involved in Vi antigen synthesis and export while repressing genes encoding flagella and the invasion-associated type III secretion system (Winter et al., 2010, 2009). The latter reduces the generation of inflammatory responses during the invasion of the intestinal mucosa (Raffatellu et al., 2007; Winter et al., 2008, 2015, 2014). More important, acquisition of the *viaB* locus by horizontal gene transfer helps explain why *S. Typhi* is able to avert the respiratory burst of neutrophils (Kossack et al., 1981; Miller et al., 1972). When a neutrophil comes within close proximity of *S. Typhimurium*, it migrates toward the intruder by following a chemotactic gradient of complement component 5 fragment a (C5a) that emanates from the bacterial surface (Wangdi et al., 2014). C5a is a neutrophil chemoattractant that triggers Rac-dependent NADPH oxidase activation (Bokoch, 1995), thereby rendering the *S. Typhimurium*-induced neutrophil oxidative burst complement dependent. The Vi antigen encoded by the *S. Typhi viaB* locus prevents complement activation and C5a-mediated neutrophil chemotaxis (Wangdi et al., 2014).

However, the *viaB* locus is not present in *S. Paratyphi A* (McClelland et al., 2004), which is puzzling because host responses elicited by this pathogen are more similar to those triggered by *S. Typhi* than those observed during *S. Typhimurium* infection. Here, we resolve this apparent paradox by showing that typhoidal *Salmonella* serovars acquired virulence traits for averting the phagocyte respiratory burst through convergent evolution.

RESULTS

Typhoidal *Salmonella* Serovars Evade the Phagocyte Respiratory Burst

To test the hypothesis that unlike non-typhoidal *Salmonella* serovars, typhoidal *Salmonella* serovars possess virulence mechanisms for averting the phagocyte respiratory burst, we infected human neutrophil-like (HL-60) cells with typhoidal and non-typhoidal *Salmonella* serovars and monitored the generation of ROS using a luminol-based bioassay. Infection with non-typhoidal *Salmonella* serovars, including *S. Typhimurium* (strains from the American Type Culture Collection [ATCC]: ATCC14028 and ATCC7823) and *S. Enteritidis* (strain SSU7998), triggered a robust respiratory burst (Figures 1A and 1B; Figure S1A). In contrast, infection of HL-60 cells with typhoidal *Salmonella* serovars, including *S. Typhi* strain ATCC700931 (Ty2) or *S. Paratyphi A* strain ATCC9150, did not elicit this response (Figures 1A and 1B). Similar results were obtained using primary human neutrophils (Figures S1B and S1C).

The Vi Antigen Enables *S. Typhi* to Avert the Phagocyte Respiratory Burst

To assess whether averting the phagocyte respiratory burst is a feature that is conserved among *S. Typhi* isolates, HL-60 cells were infected with *S. Typhi* strains Ty2, ATCC19430, and ATCC33458. Similar to *S. Typhi* strain Ty2, *S. Typhi* strain ATCC19430 did not elicit

marked ROS production in HL-60 cells. However, robust ROS production was observed with *S. Typhi* strain ATCC33458 (Figure S1A). The Vi antigen of *S. Typhi* has been implicated in averting the neutrophil respiratory burst (Kossack et al., 1981; Miller et al., 1972), and its biosynthesis is encoded by the *viaB* locus on *Salmonella* pathogenicity island (SPI) 7, a DNA region that can be lost upon laboratory passage of clinical isolates (Bueno et al., 2004; Nair et al., 2004). Interestingly, production of the Vi antigen could be detected by dot blot analysis in *S. Typhi* strains Ty2 and ATCC19430, but not in *S. Typhi* strain ATCC33458 (Figure S1D). These data suggested that robust ROS production elicited by *S. Typhi* ATCC33458 (Figure S1A) may result from the inability of the strain to produce the Vi antigen (Figure S1D). To test this idea, we compared ROS production elicited by *S. Typhi* strain Ty2 in HL-60 cells with that elicited by an isogenic mutant carrying a precise deletion of the Vi capsule biosynthesis genes (*S. Typhi tviB-vexE* mutant). Unlike *S. Typhi* strain Ty2, the non-capsulated *S. Typhi tviB-vexE* mutant elicited robust ROS production in HL-60 cells (Figures 1C and 1D). Similar results were obtained using primary human neutrophils (Figures S1E and S1F). Introduction of a plasmid (pDC5) carrying the cloned *viaB* region into the *S. Typhi tviB-vexE* mutant restored synthesis of the Vi antigen (Figure S1G) and moderated ROS production in HL-60 cells (Figures 1E and 1F).

Next, we characterized the mechanism through which the Vi antigen inhibits the neutrophil respiratory burst. The Vi antigen inhibits complement activation on the bacterial surface (Looney and Steigbigel, 1986; Wilson et al., 2011), thereby conferring serum resistance on *S. Typhi* (Figures 2A and 2B; Figure S1H) (Hart et al., 2016). We investigated whether preventing complement activation would inhibit the phagocyte respiratory burst. ROS production triggered by infecting HL-60 cells with the non-capsulated *S. Typhi tviB-vexE* mutant was complement dependent because it required opsonization with human serum (data not shown) and could be blunted by treatment with Futhan (6-amidino-2-naphthyl *p*-guanidinobenzoate dimethanesulfonate; BD Biosciences), a complement inhibitor (Figures 2C and 2D). The main conduit of lipopolysaccharide (LPS)-mediated complement activation in an immunologically naive host is mediated by binding of B-1 cell-derived natural immunoglobulin (IgM) to the bacterial surface, which leads to complement activation through the classical pathway (Reid et al., 1997). We thus determined whether IgM in human serum binds to purified LPS or to purified Vi antigen. Human IgM bound to LPS purified from *S. Typhimurium* or an *S. Typhi tviB-vexE* mutant, but it did not bind to purified Vi antigen (Figure 2E). We next investigated whether production of Vi antigen would prevent IgM binding to the bacterial surface. After incubation of bacteria in human serum, proteins bound to the surface were eluted using glycine and analyzed by western blot with anti-IgM antibody. Human IgM bound to the surface of *S. Typhimurium* (ATCC14028) and *S. Enteritidis* (SSU7998), but not to *S. Typhi* (Ty2). Inhibition of IgM binding to the surface of *S. Typhi* was mediated by the capsular polysaccharide because binding of IgM was detected at the surface of an *S. Typhi tviB-vexE* mutant (Figure 2F), which was consistent with a previous report (Hart et al., 2016).

S. Typhi carries a loss-of-function mutation in *fepE* (Bravo et al., 2008), encoding the length regulator of very long O antigen chains (Murray et al., 2003). Because human IgM bound to purified *S. Typhi* LPS (Figure 2E), we investigated whether restoring the expression of very long O antigen chains in *S. Typhi* would result in IgM binding to the bacterial surface.

Interestingly, introduction of a plasmid (pTW134) carrying the cloned *fepE* gene from *S. Paratyphi A* into *S. Typhi* resulted in the expression of very long O antigen chains (Figure S2A) and the binding of human IgM to the bacterial surface (Figure S2B), suggesting that the Vi antigen cannot prevent the binding of IgM to very long LPS species. These data were consistent with a previous report, showing that lack of very long O antigen chains is required for Vi antigen-mediated evasion of complement activation in *S. Typhi* (Crawford et al., 2013).

Very Long O Antigen Chains of *S. Paratyphi A* Inhibit the Phagocyte Respiratory Burst

To investigate the mechanism by which *S. Paratyphi A* averts the neutrophil respiratory burst, we incubated *S. Typhimurium* (ATCC14028) and *S. Paratyphi A* (ATCC9150) in human serum and analyzed proteins eluted from the bacterial surface (Figure S3A) by mass spectrometry (MS) (Figure S3B). The results showed that increased amounts of IgM and complement components were eluted from the surface of *S. Typhimurium* compared to *S. Paratyphi A* (Figure S3). Similarly, *S. Typhi* bound less IgM and complement components compared to *S. Typhimurium* (Figure S3). However, *S. Paratyphi A* reduced binding of IgM and deposition of complement through a mechanism that did not require the Vi antigen, because the biosynthesis of this capsular polysaccharide is encoded by the *viaB* locus (Liston et al., 2016; Virlogeux et al., 1995; Wetter et al., 2012), a DNA region present in *S. Typhi* but absent from *S. Paratyphi A* (Figure 2E) (McClelland et al., 2004).

Next, we investigated whether evasion of the neutrophil respiratory burst was a general feature of *S. Paratyphi A* isolates. To this end, HL-60 cells were infected with *S. Paratyphi A* var. Durazzo strain ATCC11511 and *S. Paratyphi A* strains ATCC9150 and ATCC9281. ROS production was blunted in HL-60 cells infected with *S. Paratyphi A* strains ATCC9150 and ATCC9281, but *S. Paratyphi A* var. Durazzo strain ATCC11511 elicited a robust respiratory burst (Figures 3A and 3B). The latter isolate was first described in a 1934 article cautioning that laboratory passage may have begun to alter the O antigen of *S. Paratyphi A* var. Durazzo toward a rough form (Kauffmann and Silberstein, 1934). Dot blot analysis of purified LPS suggested that the O₂ antigen, which is characteristic of *S. Paratyphi A* O antigen repeat units, was produced by all three isolates (Figure 3C). However, comparison of LPS chain lengths revealed that *S. Paratyphi A* var. Durazzo (ATCC: 11511) lacked very long O antigen chains, whereas very long O antigen chains were present in other *S. Paratyphi A* isolates (Figure 3D).

O antigen chains of *Salmonella* LPS typically exhibit a trimodal length distribution, including short LPS species containing between 1 and 15 O antigen repeat units, long LPS species carrying between 16 and 35 O antigen repeat units, and very long LPS species with >100 O antigen repeat units (Batchelor et al., 1992, 1991; Murray et al., 2003) (Figure 3D). A length regulator encoded by the *fepE* gene controls the synthesis of very long O antigen chains (Murray et al., 2003). Inspection of the genomic sequence revealed that the *fepE* gene was disrupted in *S. Paratyphi A* var. Durazzo (ATCC11511) by a frameshift mutation (i.e., insertion of an adenine nucleotide) in position 33 of the open reading frame. In contrast, the *fepE* gene was intact in the other *S. Paratyphi A* isolates. These data raised the possibility that very long O antigen chains of *S. Paratyphi A* prevented the generation of the phagocyte

respiratory burst. Remarkably, inactivation of the *fepE* gene in *S. Paratyphi* A strain ATCC9150 resulted in the loss of very long O antigen production (Figure 3E) and the generation of a robust respiratory burst (Figures 3F and 3G), whereas complementation of the mutation via the introduction of a plasmid (pTW134) carrying the cloned *fepE* gene restored the inhibition of ROS production in HL-60 cells. The *S. Paratyphi* A ATCC9150 *fepE* mutant also exhibited increased serum sensitivity compared to the wild-type or a complemented mutant (Figure S4). Introduction of a plasmid encoding an intact *fepE* gene (pTW134) into *S. Paratyphi* A var. Durazzo (ATCC11511) restored very long O antigen production (Figure 3H), restored serum resistance (Figure S4A), and abrogated ROS production in HL-60 cells (Figures 3I and 3J) and primary human neutrophils (Figures S4B and S4C). These data provided direct support for the idea that very long O antigen chains enable *S. Paratyphi* A to avert the phagocyte respiratory burst.

The O2 Antigen of *S. Paratyphi* A Reduces Antibody-Mediated ROS Production

Studies with normal human serum (NHS) from different individuals suggested that IgM binds to LPS purified from *S. Typhimurium* and *S. Typhi*, but binding to LPS purified from *S. Paratyphi* A was observed in only a fraction of individuals (Figure 2E; Figure S5). The occasional presence of IgM antibodies against *S. Paratyphi* A LPS in NHS may be the result of previous exposure to related antigens in the respective donors. However, the absence of IgM binding in a fraction of NHS samples suggested that natural antibodies did not recognize *S. Paratyphi* A LPS. Increased IgM binding to the surface of an *S. Paratyphi* A (ATCC9150) *fepE* mutant (Figure 4A) suggested that very long O antigen chains reduced IgM binding to the bacterial surface.

The O antigen of *S. Paratyphi* A is composed of an α -D-mannose-(1,4)- α -L-rhamnose-(1,3)- α -D-galactose backbone (the O12 antigen) and a branching paratose residue that is α -(1,3)-linked to D-mannose in the backbone (the O2 antigen). O antigens of *S. Typhimurium* and *S. Typhi* have an identical trisaccharide backbone (the O12 antigen), but they carry abequose (the O4 antigen) or tyvelose (the O9 antigen), respectively, as branching sugars. Interestingly, *rfbE* is a pseudogene (i.e., an open reading frame disrupted by a mutation) in *S. Paratyphi* A (Figure 4B) (McClelland et al., 2004), which prevents conversion of cytidine diphosphate (CDP)-paratose to CDP-tyvelose and accounts for the presence of paratose (the O2 antigen) in place of tyvelose (the O9 antigen), the only structural difference between the O antigens of *S. Paratyphi* A and *S. Typhi*.

To determine whether the branching paratose residue (the O2 antigen) was necessary for inhibiting ROS production, we introduced the *S. Typhi* *rfbE* gene into *S. Paratyphi* A (ATCC9150). The resulting *S. Paratyphi* A strain, henceforth referred to as *S. Paratyphi* A^{O9}, produced very long O antigen chains (Figure 4C) containing the O9 antigen instead of the O2 antigen (Figure 4D), which resulted in a robust induction of ROS production in HL-60 cells (Figures 4E and 4F) and primary human neutrophils (Figures S4D and S4E). Next, we replaced the *S. Paratyphi* A (ATCC9150) *rfbS* and *rfbE* genes, encoding paratose synthase and tyvelose epimerase, respectively, with the *S. Typhimurium* *rfbJ* gene, encoding abequose synthase (Figure 4B). The resulting *S. Paratyphi* A strain, henceforth referred to as *S. Paratyphi* A^{O4}, produced very long O antigen chains (Figure 5A) containing the O4

antigen instead of the O2 antigen (Figure 5B); this resulted in robust ROS production in HL-60 cells (Figures 5C and 5D) and primary human neutrophils (Figures S4D and S4E). Collectively, these data supported the idea that the O2 antigen is necessary for averting the neutrophil respiratory burst.

Human IgM bound to LPS purified from *S. Paratyphi A*^{O4} but not to LPS purified from *S. Paratyphi A* (ATCC9150), suggesting that the O2 antigen was responsible for poor binding of human natural antibodies to LPS (Figure 5E). Interestingly, *S. Paratyphi A* opsonized with the serum of germ-free mice elicited robust ROS production in murine primary neutrophils, suggesting that unlike human natural antibodies, the natural antibody repertoire of mice recognizes the O2 antigen (Figures S4F and S4G). We then investigated the binding of human IgM to the bacterial surface. Human IgM bound to the surface of *S. Paratyphi A*^{O4} and Paratyphi A^{O9}, but binding to the surface of *S. Paratyphi A* was reduced markedly in comparison (Figure 5F).

Next, we tested whether antibody-mediated complement activation through the classical pathway was responsible for the phagocyte respiratory burst triggered by *S. Paratyphi A*^{O4}. Blocking the classical and the alternative pathways of complement activation with EGTA abrogated ROS production elicited by *S. Paratyphi A*^{O4} in HL-60 cells. Interestingly, selective inhibition of the classical pathway with EGTA and Mg²⁺ (Des Prez et al., 1975) resulted in a marked reduction of ROS production (Figure 6A). Similarly, the classical pathway was responsible for ROS production elicited by a *fehE* mutant of *S. Paratyphi A* strain ATCC9150 (Figure S6A), although IgM did not bind LPS purified from this strain (Figure S6B). To further investigate the contribution of antibodies to the triggering of the phagocyte respiratory burst, we depleted IgM or IgG from NHS. IgM depletion, but not IgG depletion, reduced the concentration of IgM in NHS (Figure 6B). Opsonization with IgM-depleted serum lowered ROS production triggered by *S. Paratyphi A*^{O4} in HL-60 cells to levels observed with its *S. Paratyphi A* parent strain (Figure 6C). In contrast, *S. Paratyphi A*^{O4} opsonized with IgG-depleted serum triggered significantly larger ROS production in HL-60 cells than the *S. Paratyphi A* parent strain. Collectively, these data provided compelling support for the idea that the O2 antigen averts the neutrophil respiratory burst in a fraction of individuals by preventing IgM binding.

DISCUSSION

The *viaB* locus is a DNA region acquired by horizontal gene transfer that is present exclusively in *Salmonella* serovars associated with extraintestinal disease, including two human-adapted typhoidal *Salmonella* serovars, *S. Typhi* and *S. Paratyphi C* (Selander et al., 1990), and the bovine-adapted *S. Dublin*, which causes bacteremia in cattle (Selander et al., 1992). The presence of the *viaB* locus confers some of the properties that distinguish *S. Typhi* from non-typhoidal *Salmonella* serovars associated with human gastroenteritis, such as *S. Typhimurium* (Keestra-Gounder et al., 2015; Raffatellu et al., 2006; Tsolis et al., 2008; Wangdi et al., 2012). However, the *viaB* locus is absent from *S. Paratyphi A*, which is puzzling because paratyphoid fever is indistinguishable in its symptoms from typhoid fever.

S. Paratyphi A evolved from an ancestral organism producing the O₉ -antigen through a loss-of-function mutation in *rfbE*, resulting in expression of the O₂ antigen instead of the O₉ antigen (McClelland et al., 2004). Here, we show that very long O antigen chains carrying the O₂ antigen do not trigger the neutrophil respiratory burst in humans because they prevent antibody binding, at least in a fraction of individuals. By analogy, *S. Typhi* covers its surface with the Vi antigen, which does not trigger the neutrophil respiratory burst by preventing antibody binding (Hart et al., 2016). In an immunologically naive host, binding of natural IgM to the bacterial surface activates complement through the classical pathway (Reid et al., 1997), which appeared to be the main pathway leading to ROS production in neutrophils infected with non-capsulated *S. Typhi* or *S. Paratyphi A* lacking very long O antigen chains. The picture emerging from this and previous work is that polysaccharide chains can prevent complement-dependent ROS production, if they (1) do not bind natural IgM and (2) are long enough to prevent pentameric IgM molecules from gaining access to other potential binding sites at the bacterial surface (Figure 7). In support of this idea, the presence of very long O antigen chains can interfere with immune evasion by the Vi antigen (Crawford et al., 2013), presumably because the former rival the capsule in length, thereby exposing IgM binding sites at the bacterial surface (Figures 7A–7C). Furthermore, short and long O antigen chains produced by an *S. Paratyphi A* *lepE* mutant did not bind IgM, but this was not sufficient for preventing ROS production, presumably because very long O antigen chains are the only surface structures long enough to cover up other IgM binding sites (Figures 7D and 7E). These results suggested that *S. Typhi* and *S. Paratyphi A* both used very long polysaccharide chains to prevent human IgM binding, complement activation, and ROS production, a shared virulence strategy that distinguishes them from non-typhoidal *Salmonella* serovars associated with human gastroenteritis. This remarkable example of convergent evolution was not apparent from previous work focusing on horizontal gene transfer of the *viaB* locus, but it becomes apparent only when the contribution of pseudogene formation is taken into account. This situation is reminiscent of that observed during the evolution of *Yersinia pestis* from a *Yersinia pseudotuberculosis*-like ancestor, which involved a combination horizontal gene transfer (*ymt* and *pla*) and pseudogene formation (*ureD*, *rcaA*, *pde2*, and *pde3*) to complete the transition from a gastrointestinal pathogen to an arthropod-borne extraintestinal pathogen (Hinnebusch et al., 2016). Recent work suggests that the transition from a gastrointestinal to an extraintestinal pathogen involved deletion of genes encoding a pathway for anaerobic b-oxidation of butyrate in *S. Typhi* and *S. Paratyphi A*, which moderates intestinal inflammation during typhoid and paratyphoid fever (Bronner et al., 2018).

Interestingly, whereas the O₂ antigen prevented binding of human natural antibodies (Figure 5), it did not prevent opsonization with serum from germ-free mice (Figures S4F and S4G). These data indicate that unlike the natural antibody reservoir of humans, the natural antibody reservoir of mice recognizes the O₂ antigen. The O₂ antigen also is present in a small number of non-typhoidal serovars, including *S. Nitra*, *S. Kiel*, and *S. Koessen* (Grimont and Weill, 2007), that are not commonly isolated from patients or animals bred as food (Edwards et al., 1948; Hargrett-Bean et al., 1988; Rigney et al., 2004). These epidemiological observations suggest that *S. Nitra*, *S. Kiel*, and *S. Koessen* are not adapted to humans, but they may circulate in an unknown wild animal reservoir.

EXPERIMENTAL PROCEDURES

Bacterial Strains, Plasmids, and Growth Conditions

Bacterial strains used in this study are presented in Table S1. Bacterial cultures were routinely incubated with aeration at 37°C in Luria-Bertani (LB) broth (10 g tryptone, 5 g yeast extract, and 10 g NaCl/L) or on LB agar plates unless indicated otherwise. Antibiotics were added as appropriate. To induce expression of Vi capsule polysaccharide, low sodium (0.25% NaCl) was used to preculture bacterial strains.

S. Paratyphi A strain TWS110 (*rfbSE::rfbJ^{STM}*) was generated by replacing the *rfbSE* genes with the *rfbJ* gene from *S. Typhimurium* via homologous recombination. Briefly, the *S. Typhimurium rfbHJ* region was amplified with primers 83/84 (Table S2). *S. Paratyphi* A *rfbX* was amplified with primers 85/86. The two fragments were ligated in tandem and were cloned into plasmid pRDH10 using the Gibson Assembly kit (New England Biolabs). The construct was transformed into *Escherichia coli* S17 λ *pir* cells. The resulting donor strain (TWE76) was conjugated with wild-type *S. Paratyphi* A to generate strain TWS110 (*rfbSE::rfbJ^{STM}*).

To generate strain TWS159 (*S. Paratyphi* A 9150 *fepE::Kan^R*), *fepE* flanking regions 1 and 2 were amplified from *S. Paratyphi* A 9150 with primers 133/134 and 135/136, respectively. The two fragments were ligated in tandem and were cloned into plasmid pRDH10 using the Gibson Assembly kit. The construct was transformed into *E. coli* S17 λ *pir* cells. The resulting plasmid (pTW93) was isolated and digested at the engineered BamHI restriction site located between flanking regions 1 and 2. A kanamycin-resistance cassette was inserted and the plasmid (pTW117) was transformed into *E. coli* S17 λ *pir* cells. *E. coli* S17 λ *pir* (pTW117) was conjugated with *S. Paratyphi* A 9150 carrying a temperature-sensitive plasmid pSW172 that conferred carbenicillin resistance for counter selection. An exconjugant was cured of pSW172 to generate strain TWS159. To complement the mutation, *fepE* was amplified from *S. Paratyphi* A 9150 with primers 179/180 and was inserted into pWSK29.

To generate an *S. Paratyphi* A strain producing the O9 antigen (*S. Paratyphi* A 9150 *rfbE::rfbE^{STY}*), *rfbE*-flanking regions 1 and 2 were amplified from *S. Paratyphi* A 9150 with primers 171/172 and 173/174, respectively. The two fragments were ligated in tandem and were cloned into plasmid pRDH10 using the Gibson Assembly kit. The resulting plasmid (pTW126) was digested with BamHI to insert a kanamycin-resistance cassette to generate plasmid pTW131. *E. coli* S17 λ *pir* (pTW131) was conjugated with *S. Paratyphi* A 9150 (pSW172). An exconjugant was cured of pSW172 to generate *S. Paratyphi* A 9150 *rfbE* (HH121). Next, *rfbE* and its two flanking regions were amplified from *S. Typhi* with primers 86/87. The fragment was inserted into pRDH10 to generate plasmid pTW131. *E. coli* S17 λ *pir* (pTW131) was conjugated with HH121 to generate strain HH122 (*S. Paratyphi* A 9150 *rfbE::rfbE^{STY}*).

LPS Analysis

LPS was purified from overnight cultures of bacterial strains using hot-aqueous phenol extraction (Davis and Goldberg, 2012). A sensitive silverstaining protocol (Tsai and Frasch, 1982) was then used for detection of purified LPS separated by SDS-PAGE.

Animal Experiments

All of the experiments in this study were approved by the Institutional Animal Care and Use Committee at the University of California, Davis. Germ-free Swiss-Webster mice were bred in-house. Femurs collected from germ-free mice after euthanasia were used to isolate neutrophils.

Isolation of Primary Neutrophils

The University of California, Davis institutional review board approved the protocol for obtaining blood draws for this study. Human neutrophils were isolated from the peripheral blood of healthy adult donors using a procedure described previously (Lee et al., 2015).

To collect murine primary neutrophils, mice were euthanized and femurs were collected. Neutrophils were then isolated from bone marrow cell suspension using the EasySep mouse neutrophil enrichment kit (StemCell Technologies) in accordance with the manufacturer's instructions.

Serum Sensitivity Test

Bacterial cultures were resuspended and adjusted to optical density (OD) 0.1 in PBS. A total of 180 μL of cultures were then dispensed into each well of a 96-well plate, containing 20 μL of undiluted human serum. Plates were incubated at room temperature with gentle agitation for 3 hr. At each time point, 20- μL samples were collected, and the bacterial numbers were enumerated. As an alternative method, bacteria were incubated with 20% serum for 3 hr. Then, 10 μL of undiluted or 10^{-2} and 10^{-4} diluted samples were spotted on an LB plate and incubated at 37°C overnight and images captured (BioSpectrum Imaging System, UVP).

Sequence Analysis

The following reference genomes were used in this study: *S. Typhi* Ty2 (GenBank: AE014613.1), *S. Paratyphi A* 9150 (GenBank: CP000026.1), *S. Typhimurium* LT2 (GenBank: AE006468.2), and *S. Paratyphi A* var. Durazzo 11511 gene (GenBank: CP019185.1). To verify the *S. Paratyphi A* 11511 *fehE* nucleotide sequence, the gene was amplified with primers 137/138 and cloned into plasmid PCR2.1 to yield pTW128. For amino acid sequence alignment, Clustal Omega (<https://www.ebi.ac.uk/Tools/msa/clustalo>) was used.

ROS Assay

ROS production by HL-60 cells or primary neutrophils was measured using chemiluminescence. HL-60 cells were differentiated into neutrophil-like cells by incubation with RPMI 1640 medium (Thermo Fisher Scientific) containing 1.3% DMSO (Sigma), 15%

fetal bovine serum (FBS, Thermo Fisher Scientific) and 25 mM HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), Thermo Fisher Scientific) for 5–6 days. Differentiated HL-60 cells or primary neutrophils were washed and resuspended in phenol red free RPMI 1640 containing 2% FBS and luminol (Sigma) was added (1 mM). Approximately 5×10^4 HL-60 cells in 90 μ L were seeded into an opaque 96-well microplate (Perkin-Elmer) and the basal luminescence was measured every 2 min for 5 min on a FilterMax F3 plate reader (Molecular Devices). HL-60 cells were infected with 10 μ L of bacteria (MOI = 10) opsonized with 20% human serum (30 min at room temperature) or were mock treated, and ROS production was measured every 2 min using a plate reader. In some experiments, human serum was treated with Futhan, 10 mM EGTA, or 10 mM Mg^{2+} plus 10 mM EGTA (MgEGTA) before opsonizing bacteria.

Dot Blot Assay

LPS was purified using an LPS extraction kit (iNtRON Biotechnology). Vi capsule polysaccharide was purified essentially as described for capsular polysaccharides from *Bacteroides fragilis* (Pantosti et al., 1991). Briefly, frozen cell pellets of *S. Typhi* strain Ty2 were lysed and extracted with 37% phenol (Sigma) in water at 68°C with vigorous agitation. The aqueous phase was collected and extracted with ethyl ether (Thermo Fisher Scientific) to remove the remaining phenol, and the ether was removed from the aqueous phase on a rotary evaporator (BUCHI) at 60°C for 2 hr. DNA and RNA were eliminated from the sample by DNase and RNase (both Worthington Biochemical) digestion, respectively, and protein removed by serial digests with Pronase (Calbiochem). Polysaccharide was then harvested by ethanol precipitation and separated from LPS on a Sephacryl S300 (GE Healthcare) column in 3% deoxycholate (Sigma).

Purified LPS at 5 μ L or Vi capsule polysaccharide (100 μ g/mL) were spotted onto a nitrocellulose membrane and air dried. The membrane was blocked with 5% skim milk in PBS-T (PBS containing 0.25% Tween 20). To detect specific O antigens or Vi capsule polysaccharide, we used anti-O2, -O4, -O9, or anti-Vi capsule polysaccharide polyclonal antibodies (BD Biosciences), respectively, and secondary horseradish peroxidase (HRP)-anti-rabbit Ig. To assess IgM binding to LPS or Vi capsule polysaccharide, the membrane was incubated with diluted (1/1000–1/5000) human serum overnight at 4°C. Bound IgM was detected using HRP-anti-human IgM (Jackson ImmunoResearch). Enhanced chemiluminescence (ECL; PerkinElmer) was used to develop, and images were obtained on an imager (BioSpectrum Imaging System, UVP).

IgM Binding

To assess human IgM binding to the surface of bacterial cells, 1×10^9 colony-forming units (CFUs) of the indicated bacterial strains were incubated with 500 μ L of 20% NHS (heat inactivated) or PBS for 1 hr at room temperature. After washing the bacteria with PBS four times, bound serum proteins were eluted by resuspending the samples in 100 μ L of 0.1 M glycine-HCl followed by centrifugation. A total of 80 μ L supernatants were collected and subsequently neutralized with 20 μ L of 1 M (tris(hydroxymethyl)aminomethane) (Tris)-HCl buffer (pH 8.0). Neutralized samples and bacterial pellets were precipitated with methanol-chloroform and resuspended with Laemmli sample buffer. Samples were subjected to 10%

SDS-PAGE gel. After electrotransfer, the polyvinylidene fluoride (PVDF) membranes (Merck Millipore) were probed with HRP-conjugated anti-human IgM antibody (Jackson ImmunoResearch). As an internal control, bacterial pellets were separated by SDS-PAGE, blotted onto PVDF, and probed with anti-GroEL (Sigma). The blots were developed using ECL (PerkinElmer), and images were obtained on an imager (BioSpectrum Imaging System, UVP).

MS

Proteins eluted from the bacterial surface were analyzed by MS. Briefly, 5×10^8 CFU of bacteria were incubated with 500 μ L of 20% NHS, heat-inactivated 20% NHS, or PBS for 40 min at room temperature. Bacterial pellets were spun down and washed with PBS four times. Bound serum proteins and some bacterial proteins were eluted in 100 μ L of 0.1 M glycine-HCl (pH 2.7). Supernatants (80 μ L) were neutralized by adding 20 μ L of 1 M Tris (pH 8.0). Samples were then precipitated using methanol-chloroform. The precipitated pellets were resuspended in 60 μ L SDS-sample buffer and purified by PAGE followed by MS analysis by the Proteomics Core Facility at the University of California, Davis Genome Center.

Statistical Analysis

All of the data are expressed as the mean and standard error of the mean. Student's t tests were used for statistical analyses. $p < 0.05$ was considered significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge expert technical assistance by Brett S. Phinney and Michelle Salemi from the University of California, Davis Proteomics Core Facility. We thank Sumathi Sankaran and Briana Young for expert technical assistance. H.H. was supported by a fellowship from the Daiichi Sankyo Foundation of Life Sciences, Japan. B.A.C. was supported by Public Health Service grant GM082916. T.W. was supported by Public Health Service grant AI126080. Work in A.J.B.'s laboratory was supported by Public Health Service grants AI044170, AI096528, AI112445, and AI112949.

References

- Batchelor RA, Haraguchi GE, Hull RA, Hull SI. Regulation by a novel protein of the bimodal distribution of lipopolysaccharide in the outer membrane of Escherichia coli. *J Bacteriol.* 1991; 173:5699–5704. [PubMed: 1715860]
- Batchelor RA, Alifano P, Biffali E, Hull SI, Hull RA. Nucleotide sequences of the genes regulating O-polysaccharide antigen chain length (rol) from Escherichia coli and Salmonella typhimurium: protein homology and functional complementation. *J Bacteriol.* 1992; 174:5228–5236. [PubMed: 1379582]
- Bokoch GM. Chemoattractant signaling and leukocyte activation. *Blood.* 1995; 86:1649–1660. [PubMed: 7654998]
- Bravo D, Silva C, Carter JA, Hoare A, Alvarez SA, Blondel CJ, Zaldívar M, Valvano MA, Contreras I. Growth-phase regulation of lipopolysaccharide O-antigen chain length influences serum resistance in serovars of Salmonella. *J Med Microbiol.* 2008; 57:938–946. [PubMed: 18628492]

- Bronner DN, Faber F, Olsan EE, Byndloss MX, Sayed NA, Xu G, Yoo W, Kim D, Ryu S, Lebrilla CB, et al. Genetic ablation of butyrate utilization attenuates gastrointestinal *Salmonella* disease. *Cell Host Microbe*. 2018; 23:266–273. this issue. [PubMed: 29447698]
- Bueno SM, Santiviago CA, Murillo AA, Fuentes JA, Trombert AN, Rodas PI, Youderian P, Mora GC. Precise excision of the large pathogenicity island, SPI7, in *Salmonella enterica* serovar Typhi. *J Bacteriol*. 2004; 186:3202–3213. [PubMed: 15126483]
- Crawford RW, Wangdi T, Spees AM, Xavier MN, Tsolis RM, Bäumlér AJ. Loss of very-long O-antigen chains optimizes capsule-mediated immune evasion by *Salmonella enterica* serovar Typhi. *MBio*. 2013; 4:e00232–13. [PubMed: 23860765]
- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ*. 2004; 82:346–353. [PubMed: 15298225]
- Davis MR Jr, Goldberg JB. Purification and visualization of lipopolysaccharide from Gram-negative bacteria by hot aqueous-phenol extraction. *J Vis Exp*. 2012; (63):3916. [PubMed: 22688346]
- Des Prez RM, Bryan CS, Hawiger J, Colley DG. Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl₂-ethylene glycol tetraacetic acid. *Infect Immun*. 1975; 11:1235–1243. [PubMed: 806523]
- Edwards PR, Bruner DW, Moran AB. Further studies on the occurrence and distribution of *Salmonella* types in the United States. *J Infect Dis*. 1948; 83:220–231. [PubMed: 18101741]
- Grimont, PAD., Weill, F-X. WHO Collaborating Centre for Reference and Research on *Salmonella*. Ninth Edition. 2007. Antigenic Formulae of the *Salmonella* Serovars.
- Hargrett-Bean NT, Pavia AT, Tauxe RV. *Salmonella* isolates from humans in the United States, 1984-1986. *MMWR CDC Surveill Summ*. 1988; 37:25–31.
- Hart PJ, O'Shaughnessy CM, Siggins MK, Bobat S, Kingsley RA, Goulding DA, Crump JA, Reyburn H, Micoli F, Dougan G, et al. Differential killing of *Salmonella enterica* serovar Typhi by antibodies targeting Vi and lipopolysaccharide O:9 antigen. *PLoS One*. 2016; 11:e0145945. [PubMed: 26741681]
- Hinnebusch BJ, Chouikha I, Sun YC. Ecological opportunity, evolution, and the emergence of flea-borne plague. *Infect Immun*. 2016; 84:1932–1940. [PubMed: 27160296]
- Hohn DC, Lehrer RI. NADPH oxidase deficiency in X-linked chronic granulomatous disease. *J Clin Invest*. 1975; 55:707–713. [PubMed: 235560]
- Kauffmann F, Silberstein W. Untersuchungen über einige neue *Salmonella*-typen. *Zentralbl Bakteriell Parasitenkd Infektionskr*. 1934; 132:431–437.
- Keestra-Gounder AM, Tsolis RM, Bäumlér AJ. Now you see me, now you don't: the interaction of *Salmonella* with innate immune receptors. *Nat Rev Microbiol*. 2015; 13:206–216. [PubMed: 25749454]
- Kossack RE, Guerrant RL, Densen P, Schadelin J, Mandell GL. Diminished neutrophil oxidative metabolism after phagocytosis of virulent *Salmonella typhi*. *Infect Immun*. 1981; 31:674–678. [PubMed: 7216467]
- Lee CY, Thompson GR 3rd, Hastey CJ, Hodge GC, Lunetta JM, Pappagianis D, Heinrich V. *Coccidioides* endospores and spherules draw strong chemotactic, adhesive, and phagocytic responses by individual human neutrophils. *PLoS One*. 2015; 10:e0129522. [PubMed: 26070210]
- Liston SD, Ovchinnikova OG, Whitfield C. Unique lipid anchor attaches Vi antigen capsule to the surface of *Salmonella enterica* serovar Typhi. *Proc Natl Acad Sci USA*. 2016; 113:6719–6724. [PubMed: 27226298]
- Looney RJ, Steigbigel RT. Role of the Vi antigen of *Salmonella typhi* in resistance to host defense in vitro. *J Lab Clin Med*. 1986; 108:506–516. [PubMed: 3021879]
- McClelland M, Sanderson KE, Clifton SW, Latreille P, Porwollik S, Sabo A, Meyer R, Bieri T, Ozersky P, McLellan M, et al. Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of *Salmonella enterica* that cause typhoid. *Nat Genet*. 2004; 36:1268–1274. [PubMed: 15531882]
- McPhail LC, DeChatelet LR, Shirley PS, Wilfert C, Johnston RB Jr, McCall CE. Deficiency of NADPH oxidase activity in chronic granulomatous disease. *J Pediatr*. 1977; 90:213–217. [PubMed: 12254]

- Miller RM, Garbus J, Hornick RB. Lack of enhanced oxygen consumption by polymorphonuclear leukocytes on phagocytosis of virulent *Salmonella typhi*. *Science*. 1972; 175:1010–1011. [PubMed: 5009393]
- Moellering RC Jr, Weinberg AN. Persistent *Salmonella* infection in a female carrier for chronic granulomatous disease. *Ann Intern Med*. 1970; 73:595–601. [PubMed: 5506010]
- Murray GL, Attridge SR, Morona R. Regulation of *Salmonella typhimurium* lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a second Wzz. *Mol Microbiol*. 2003; 47:1395–1406. [PubMed: 12603743]
- Nair S, Alokam S, Kothapalli S, Porwollik S, Proctor E, Choy C, McClelland M, Liu SL, Sanderson KE. *Salmonella enterica* serovar Typhi strains from which SPI7, a 134-kilobase island with genes for Vi exopolysaccharide and other functions, has been deleted. *J Bacteriol*. 2004; 186:3214–3223. [PubMed: 15126484]
- Nuccio, S-P., Wangdi, T., Winter, SE., Baumler, AJ. Typhoid. In: Rosenberg, E.DeLong, EF.Lory, S.Stackebrandt, E., Thompson, F., editors. *The Prokaryotes*. Springer-Verlag; 2013. p. 353-374.
- Pantosti A, Tzianabos AO, Onderdonk AB, Kasper DL. Immunochemical characterization of two surface polysaccharides of *Bacteroides fragilis*. *Infect Immun*. 1991; 59:2075–2082. [PubMed: 2037368]
- Raffatellu M, Chessa D, Wilson RP, Tükel C, Akçelik M, Bäumlner AJ. Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis. *Infect Immun*. 2006; 74:19–27. [PubMed: 16368953]
- Raffatellu M, Santos RL, Chessa D, Wilson RP, Winter SE, Rossetti CA, Lawhon SD, Chu H, Lau T, Bevins CL, et al. The capsule encoding the *viaB* locus reduces interleukin-17 expression and mucosal innate responses in the bovine intestinal mucosa during infection with *Salmonella enterica* serotype. Typhi *Infect Immun*. 2007; 75:4342–4350. [PubMed: 17591794]
- Reid RR, Prodeus AP, Khan W, Hsu T, Rosen FS, Carroll MC. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. *J Immunol*. 1997; 159:970–975. [PubMed: 9218618]
- Rigney CP, Salamone BP, Anandaraman N, Rose BE, Umholtz RL, Ferris KE, Parham DR, James W. *Salmonella* serotypes in selected classes of food animal carcasses and raw ground products, January 1998 through December 2000. *J Am Vet Med Assoc*. 2004; 224:524–530. [PubMed: 14989544]
- Seger RA, Tiefenauer L, Matsunaga T, Wildfeuer A, Newburger PE. Chronic granulomatous disease due to granulocytes with abnormal NADPH oxidase activity and deficient cytochrome-b. *Blood*. 1983; 61:423–428. [PubMed: 6297635]
- Selander RK, Beltran P, Smith NH, Helmuth R, Rubin FA, Kopecko DJ, Ferris K, Tall BD, Cravioto A, Musser JM. Evolutionary genetic relationships of clones of *Salmonella* serovars that cause human typhoid and other enteric fevers. *Infect Immun*. 1990; 58:2262–2275. [PubMed: 1973153]
- Selander RK, Smith NH, Li J, Beltran P, Ferris KE, Kopecko DJ, Rubin FA. Molecular evolutionary genetics of the cattle-adapted serovar *Salmonella dublin*. *J Bacteriol*. 1992; 174:3587–3592. [PubMed: 1592813]
- Tsai CM, Frasch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. *Anal Biochem*. 1982; 119:115–119. [PubMed: 6176137]
- Tsolis RM, Young GM, Solnick JV, Bäumlner AJ. From bench to bedside: stealth of enteroinvasive pathogens. *Nat Rev Microbiol*. 2008; 6:883–892. [PubMed: 18955984]
- Virlogeux I, Waxin H, Ecobichon C, Popoff MY. Role of the *viaB* locus in synthesis, transport and expression of *Salmonella typhi* Vi antigen. *Microbiology*. 1995; 141:3039–3047. [PubMed: 8574397]
- Wangdi T, Winter SE, Bäumlner AJ. Typhoid fever: “you can’t hit what you can’t see”. *Gut Microbes*. 2012; 3:88–92. [PubMed: 22156762]
- Wangdi T, Lee C-Y, Spees AM, Yu C, Kingsbury DD, Winter SE, Hasteley CJ, Wilson RP, Heinrich V, Bäumlner AJ. The Vi capsular polysaccharide enables *Salmonella enterica* serovar typhi to evade microbe-guided neutrophil chemotaxis. *PLoS Pathog*. 2014; 10:e1004306. [PubMed: 25101794]

- Wetter M, Goulding D, Pickard D, Kowarik M, Waechter CJ, Dougan G, Wacker M. Molecular characterization of the *viaB* locus encoding the biosynthetic machinery for Vi capsule formation in *Salmonella* Typhi. *PLoS One*. 2012; 7:e45609. [PubMed: 23029132]
- Wilson RP, Winter SE, Spees AM, Winter MG, Nishimori JH, Sanchez JF, Nuccio SP, Crawford RW, Tükel ç, Bäumlér AJ. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of *Salmonella enterica* serotype Typhi. *Infect Immun*. 2011; 79:830–837. [PubMed: 21098104]
- Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. *Medicine (Baltimore)*. 2000; 79:155–169. [PubMed: 10844935]
- Winter SE, Raffatellu M, Wilson RP, Rüssmann H, Bäumlér AJ. The *Salmonella enterica* serotype Typhi regulator TviA reduces interleukin-8 production in intestinal epithelial cells by repressing flagellin secretion. *Cell Microbiol*. 2008; 10:247–261. [PubMed: 17725646]
- Winter SE, Winter MG, Thiennimitr P, Gerriets VA, Nuccio SP, Rüssmann H, Bäumlér AJ. The TviA auxiliary protein renders the *Salmonella enterica* serotype Typhi RcsB regulon responsive to changes in osmolarity. *Mol Microbiol*. 2009; 74:175–193. [PubMed: 19703107]
- Winter SE, Winter MG, Godinez I, Yang H-J, Rüssmann H, Andrews-Polymeris HL, Bäumlér AJ. A rapid change in virulence gene expression during the transition from the intestinal lumen into tissue promotes systemic dissemination of *Salmonella*. *PLoS Pathog*. 2010; 6:e1001060. [PubMed: 20808848]
- Winter SE, Winter MG, Poon V, Keestra AM, Sterzenbach T, Faber F, Costa LF, Cassou F, Costa EA, Alves GE, et al. *Salmonella enterica* serovar Typhi conceals the invasion-associated type three secretion system from the innate immune system by gene regulation. *PLoS Pathog*. 2014; 10:e1004207. [PubMed: 24992093]
- Winter SE, Winter MG, Atluri V, Poon V, Romão EL, Tsohis RM, Bäumlér AJ. The flagellar regulator TviA reduces pyroptosis by *Salmonella enterica* serovar Typhi. *Infect Immun*. 2015; 83:1546–1555. [PubMed: 25644011]

In Brief

The clinical presentation of typhoid fever differs from gastroenteritis, which has been attributed to the *Salmonella enterica* serovar (*S.*) Typhi capsular polysaccharide. Paradoxically, *S.* Paratyphi A is not capsulated but causes typhoid-like disease. Hiyoshi et al. show that the very long O antigen of *S.* Paratyphi A functions as a capsule, an example of convergent evolution.

Highlights

- Typhoidal but not non-typhoidal *Salmonella* serovars foil the PMN respiratory burst
- The Vi antigen averts binding of natural antibodies to foil the PMN respiratory burst
- *S. Paratyphi A* very long O antigen chains foil the PMN respiratory burst
- Virulence in typhoidal *Salmonella* serovars arose through convergent evolution




Figure 1. *S. Typhi* Evades the Respiratory Burst in Neutrophil-like Cells Using the Vi Antigen
 HL-60 cells were infected with the indicated opsonized bacterial strains and ROS production monitored over time using chemiluminescence.

(A and B) HL60 cells were infected with the indicated *Salmonella* serovars.

(C and D) HL60 cells were infected with capsulated and non-capsulated *S. Typhi* strains.

(E and F) HL60 cells were infected with *S. Typhi* wild type, a *tviB-vexE* mutant and a *tviB-vexE* mutant complemented by introducing the *viaB* locus on a plasmid (pDC5).

(A, C, and E) Representative experiment showing generation of chemiluminescence over time.

(B, D, and F) Quantification of chemiluminescence from three independent experiments at the indicated time point after infection. Bars represent means \pm SE. Mock, mock infection; pDC5, XX; RLU, relative luminescence units. * $p < 0.05$; ** $p < 0.01$.




Figure 2. The Vi Antigen Averts the Phagocyte Respiratory Burst by Inhibiting Antibody-Dependent Complement Activation

(A) Viability of the indicated bacterial strains incubated in 10% NHS was monitored over time.

(B) Viability of the indicated bacterial strains incubated in PBS, 20% NHS, or 20% NHS supplemented with Futhan was determined by spotting serial dilutions on agar plates.

(C and D) HL-60 cells were infected with the indicated opsonized bacterial strains and ROS production monitored over time using chemiluminescence.

(C) Representative experiment showing generation of chemiluminescence over time.

(D) Quantification of chemiluminescence from three independent experiments at the indicated time point after infection.

(E) Binding of IgM in human serum (α -IgM; top); binding of rabbit anti-Vi antigen serum (α -Vi; middle); or binding of rabbit anti-O2, -O4, -O9 serum (α -O2, O4, O9; bottom panel) to purified LPS of the indicated bacterial strains or to purified Vi antigen was detected by dot blot.

(F) The indicated bacterial strains were incubated in human serum and surface-bound proteins eluted with glycine. IgM eluted from the bacterial surface was detected by western blot (α -IgM; top). The bacterial protein GroEL was detected in the bacterial pellet (α -GroEL; bottom) and used as a loading control by measuring the IgM/GroEL using densitometry.

(A and D) Bars represent means \pm SE.

Mock, mock infection; RLU, relative luminescence units. ****** $p < 0.01$.




Figure 3. Very Long O Antigen Chains of *S. Paratyphi A* Are Necessary for Evasion of the Respiratory Burst in Neutrophil-like Cells

(A and B) HL-60 cells were infected with the indicated opsonized *S. Paratyphi A* or *S. Paratyphi A* var. Durazzo strains and ROS production monitored over time using chemiluminescence.

(C) Production of the O₂-antigen was detected in LPS purified from the indicated bacterial strains using rabbit anti-O₂ serum.

(D) LPS purified from the indicated *S. Paratyphi A* or *S. Paratyphi A* var. Durazzo strains was separated by SDS-PAGE and silver stained.

(E) LPS purified from *S. Paratyphi A* strain ATCC9150, an isogenic *fehE* mutant or a complemented *fehE* mutant was separated by SDS-PAGE and silver stained.

(F and G) *S. Paratyphi A* strain ATCC9150, an isogenic *fehE* mutant or a complemented *fehE* mutant were opsonized and ROS production elicited after infection of HL-60 cells monitored over time using chemiluminescence.

(H) LPS purified from the indicated *S. Paratyphi A* var. Durazzo strains was separated by SDS-PAGE and silver stained.

(I and J) HL-60 cells were infected with the indicated opsonized *S. Paratyphi A* var. Durazzo strains and ROS production monitored over time using chemiluminescence.

(A, B, F, G, I, and J) HL-60 cells were infected with the indicated opsonized bacterial strains and ROS production monitored over time using chemiluminescence.

(A, F, and I) Representative experiments showing generation of chemiluminescence over time.

(B, G, and J) Quantification of chemiluminescence from three independent experiments at the indicated time point after infection. Bars represent means ± SE. L, long O antigen chains; Mock, mock infection; pTW134, plasmid carrying the cloned *fehE* gene from *S. Paratyphi A* strain ATCC9150; pWSK29, cloning vector; RLU, relative luminescence units;

S, short O antigen chains; VL, very long O antigen chains; ; 9150, *S. Paratyphi* A strain ATCC9150; 9281, *S. Paratyphi* A strain ATCC9281; 11511, *S. Paratyphi* A var. Durazzo strain ATCC11511. **p < 0.01.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Heterologous Production of the O9 Antigen by *S. Paratyphi A* Activates the Respiratory Burst in Neutrophil-like Cells

(A) The indicated *S. Paratyphi A* strains were incubated in human serum and surface-bound proteins eluted with glycine. IgM eluted from the bacterial surface was detected by western blot (α -IgM; top). The bacterial protein GroEL was detected in the bacterial pellet (α -GroEL; bottom) and used as a loading control by measuring the IgM/GroEL using densitometry.

(B) Schematic of the O antigen biosynthesis gene clusters in the indicated *Salmonella* serovars.

(C) LPS purified from the indicated bacterial strains was separated by SDS-PAGE and silver stained.

(D) LPS purified from the indicated bacterial strains was loaded on a dot blot to detect binding of IgM present in NHS (α -IgM; top), production of the O2 antigen (α -O2; middle), or production of the O9 antigen (α -O9; bottom).

(E and F) HL-60 cells were infected with the indicated opsonized bacterial strains and ROS production monitored over time using chemiluminescence.

(E) Representative experiment showing generation of chemiluminescence over time.

(F) Quantification of chemiluminescence from four independent experiments at the indicated time point after infection. Bars represent means \pm SE.

Ψ , pseudogene; L, long O antigen chains; Mock, mock infection; RLU, relative luminescence units; S, short O antigen chains; VL, very long O antigen chains. ** $p < 0.01$.




Figure 5. Heterologous Production of the O4 Antigen by *S. Paratyphi A* Activates the Respiratory Burst in Neutrophil-like Cells

(A) LPS purified from the indicated bacterial strains was separated by SDS-PAGE and silver stained.

(B) LPS purified from the indicated bacterial strains was loaded on a dot blot to detect production of the O2 antigen (α -O2; top) or production of the O4 antigen (α -O4; bottom).

(C and D) HL-60 cells were infected with the indicated opsonized bacterial strains and ROS production monitored over time using chemiluminescence. (C) Representative experiment showing generation of chemiluminescence over time.

(D) Quantification of chemiluminescence from four independent experiments at the indicated time point after infection. Bars represent means \pm SE.

(E) LPS purified from the indicated bacterial strains was loaded on a dot blot to detect binding of IgM present in NHS (α -IgM).

(F) The indicated bacterial strains were incubated in human serum and surface-bound proteins eluted with glycine. IgM eluted from the bacterial surface was detected by western blot (α -IgM; top). The bacterial protein GroEL was detected in the bacterial pellet (α -GroEL; bottom) and used as a loading control by measuring the IgM/GroEL using densitometry. L, long O antigen chains; Mock, mock infection; RLU, relative luminescence units; S, short O antigen chains; SN, supernatant; VL, very long O antigen chains. * $p < 0.05$.




Figure 6. Heterologous Production of the O4 Antigen by *S. Paratyphi A* Activates the Respiratory Burst in Neutrophil-like Cells through Antibody-Mediated Complement Activation

(A) HL60 cells were infected with the indicated opsonized bacterial strains and ROS production in the presence (+) or absence (-) of EGTA and magnesium (Mg²⁺) was monitored over time using chemiluminescence.

(B) The indicated serum dilutions were applied to a dot blot to detect the presence of IgM using anti-human IgM antibody (α-IgM).

(C) HL60 cells were infected with the indicated bacterial strains opsonized with IgG-depleted serum or IgM-depleted serum and ROS production monitored over time using chemiluminescence.

(A and C) Chemiluminescence was quantified from three independent experiments at the indicated time point after infection. Bars represent means ± standard error.

Mock, mock infection; NS, not statistically significantly different; RLU, relative luminescence units; wt, wild-type. *p < 0.05; **p < 0.001.




Figure 7. Model for Evasion of the Phagocyte Respiratory Burst by Typhoidal *Salmonella* Serovars

(A) The polysaccharide chains of the Vi antigen shield underlying surface structures from IgM binding.

(B) Restoration of the *fepE* pseudogene ($\Psi fepE$) in *S. Typhi* results in production of very long O antigen chains that rival the Vi antigen in length, thereby elevating IgM binding to the bacterial surface.

(C) Deletion of the capsule biosynthesis genes in the *S. Typhi* *tviB-vexE* mutant exposes the short and long O antigen chains, thereby resulting in IgM binding.

(D) The very long O antigen chains of *S. Paratyphi A* contain the O2 antigen, which does not bind natural IgM, thereby shielding underlying surface structures.

(E) The short and long O antigen chains present in an *S. Paratyphi A* *fepE* mutant do not bind IgM, but are too short to prevent IgM binding to other surface antigens. Ag, antigens; CM, plasma membrane; L, long O antigen chains; OM, outer membrane; S, short O antigen chains; Vi, Vi antigen; VL, very long O antigen chains.